Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol™ 15LV filaments for Fused Filament Fabrication (FFF) 3D printing

Research output: Contribution to journalArticle

Abstract

The aim of the present work was to develop a pilot scale process to produce drug-loaded filaments for 3D printing of oral solid dose forms by fused filament fabrication (FFF). Using hot melt extrusion, a viable operating space and understanding of processing limits were established using a hydrophilic polymer (hydroxypropyl methylcellulose (HPMC) - Affinisol™ LV15). This was then extended to formulate paracetamol (PCM) loaded Affinisol™ 15LV filaments across a wide range of compositions (5 - 50 wt% drug). From the process development work, challenges in achieving a pilot scale process for filament production for pharmaceutical applications have been highlighted. 3D printing trials across the range of compositions demonstrated limitations concerning the ability to print successfully across all compositions. Results from characterisation techniques including thermal and mechanical testing when applied to the formulated filaments indicated that these techniques are a useful predictive measure for assessing the ability to print a given formulation via filament methods. Oral solid dosage forms of variable surface area to mass ratios printed from suitable filament compositions demonstrated the ability to modify the release rates of drug for fixed formulations across substantial timescales.
LanguageEnglish
Article number100776
Number of pages16
JournalAdditive Manufacturing
Volume29
Early online date2 Jul 2019
DOIs
Publication statusE-pub ahead of print - 2 Jul 2019

Fingerprint

Extrusion
Printing
Fabrication
Chemical analysis
Pharmaceutical Preparations
Drug Compounding
Dosage Forms
Acetaminophen
Mechanical testing
Polymers
Hot Temperature
Drug products
Three Dimensional Printing
Processing
Hypromellose Derivatives

Keywords

  • fused filament fabrication (FFF)
  • hot melt extrusion
  • oral solid dosage form
  • hydroxypropyl methylcellulose
  • modified release paracetamol

Cite this

@article{a6a35279936f46bba984ac986fd55d52,
title = "Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol™ 15LV filaments for Fused Filament Fabrication (FFF) 3D printing",
abstract = "The aim of the present work was to develop a pilot scale process to produce drug-loaded filaments for 3D printing of oral solid dose forms by fused filament fabrication (FFF). Using hot melt extrusion, a viable operating space and understanding of processing limits were established using a hydrophilic polymer (hydroxypropyl methylcellulose (HPMC) - Affinisol™ LV15). This was then extended to formulate paracetamol (PCM) loaded Affinisol™ 15LV filaments across a wide range of compositions (5 - 50 wt{\%} drug). From the process development work, challenges in achieving a pilot scale process for filament production for pharmaceutical applications have been highlighted. 3D printing trials across the range of compositions demonstrated limitations concerning the ability to print successfully across all compositions. Results from characterisation techniques including thermal and mechanical testing when applied to the formulated filaments indicated that these techniques are a useful predictive measure for assessing the ability to print a given formulation via filament methods. Oral solid dosage forms of variable surface area to mass ratios printed from suitable filament compositions demonstrated the ability to modify the release rates of drug for fixed formulations across substantial timescales.",
keywords = "fused filament fabrication (FFF), hot melt extrusion, oral solid dosage form, hydroxypropyl methylcellulose, modified release paracetamol",
author = "Elke Prasad and Islam, {Muhammad T.} and Goodwin, {Daniel J.} and Megarry, {Andrew J.} and Halbert, {Gavin W.} and Florence, {Alastair J.} and John Robertson",
year = "2019",
month = "7",
day = "2",
doi = "10.1016/j.addma.2019.06.027",
language = "English",
volume = "29",
journal = "Additive Manufacturing",
issn = "2214-7810",

}

TY - JOUR

T1 - Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol™ 15LV filaments for Fused Filament Fabrication (FFF) 3D printing

AU - Prasad, Elke

AU - Islam, Muhammad T.

AU - Goodwin, Daniel J.

AU - Megarry, Andrew J.

AU - Halbert, Gavin W.

AU - Florence, Alastair J.

AU - Robertson, John

PY - 2019/7/2

Y1 - 2019/7/2

N2 - The aim of the present work was to develop a pilot scale process to produce drug-loaded filaments for 3D printing of oral solid dose forms by fused filament fabrication (FFF). Using hot melt extrusion, a viable operating space and understanding of processing limits were established using a hydrophilic polymer (hydroxypropyl methylcellulose (HPMC) - Affinisol™ LV15). This was then extended to formulate paracetamol (PCM) loaded Affinisol™ 15LV filaments across a wide range of compositions (5 - 50 wt% drug). From the process development work, challenges in achieving a pilot scale process for filament production for pharmaceutical applications have been highlighted. 3D printing trials across the range of compositions demonstrated limitations concerning the ability to print successfully across all compositions. Results from characterisation techniques including thermal and mechanical testing when applied to the formulated filaments indicated that these techniques are a useful predictive measure for assessing the ability to print a given formulation via filament methods. Oral solid dosage forms of variable surface area to mass ratios printed from suitable filament compositions demonstrated the ability to modify the release rates of drug for fixed formulations across substantial timescales.

AB - The aim of the present work was to develop a pilot scale process to produce drug-loaded filaments for 3D printing of oral solid dose forms by fused filament fabrication (FFF). Using hot melt extrusion, a viable operating space and understanding of processing limits were established using a hydrophilic polymer (hydroxypropyl methylcellulose (HPMC) - Affinisol™ LV15). This was then extended to formulate paracetamol (PCM) loaded Affinisol™ 15LV filaments across a wide range of compositions (5 - 50 wt% drug). From the process development work, challenges in achieving a pilot scale process for filament production for pharmaceutical applications have been highlighted. 3D printing trials across the range of compositions demonstrated limitations concerning the ability to print successfully across all compositions. Results from characterisation techniques including thermal and mechanical testing when applied to the formulated filaments indicated that these techniques are a useful predictive measure for assessing the ability to print a given formulation via filament methods. Oral solid dosage forms of variable surface area to mass ratios printed from suitable filament compositions demonstrated the ability to modify the release rates of drug for fixed formulations across substantial timescales.

KW - fused filament fabrication (FFF)

KW - hot melt extrusion

KW - oral solid dosage form

KW - hydroxypropyl methylcellulose

KW - modified release paracetamol

U2 - 10.1016/j.addma.2019.06.027

DO - 10.1016/j.addma.2019.06.027

M3 - Article

VL - 29

JO - Additive Manufacturing

T2 - Additive Manufacturing

JF - Additive Manufacturing

SN - 2214-7810

M1 - 100776

ER -